EPISODE · Aug 25, 2022 · 32 MIN
Are We Ready for More BTK Inhibitors in Chronic Lymphoblastic Leukemia? Experts Discuss the Latest Data
from Keeping Current CME
Did you know that noncovalent Bruton tyrosine kinase (BTK) inhibitors are a potential solution to overcome the challenge of covalent BTK inhibitor resistance in chronic lymphoblastic leukemia (CLL)? Credit available for this activity expires: 8/24/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/979645?src=mkm_podcast_addon_979645
Embed this episode
NOW PLAYING
Are We Ready for More BTK Inhibitors in Chronic Lymphoblastic Leukemia? Experts Discuss the Latest Data
0:00
32:10
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Keeping Current CME?
This episode is 32 minutes long.
When was this Keeping Current CME episode published?
This episode was published on August 25, 2022.
Can I download this Keeping Current CME episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!